Sat-16-07-2016, 22:22 PM
The idea that ldn will never be evaluated for other conditions because it is out of patent has confounding precedents. Thalidomide's resurrection as a treatment for myeloma and DMF's Tecfidera alter ego are examples. There have been evaluations of ldn such as Glasgow 2013 for psoriasis and Ojai Foundation's HIV trial (2008-2010), but there seems to be a paucity of results. A failure to release results does not fill me with optimism.